title: Development and testing of low-volume hyperoncotic, hyperosmotic spray-dried plasma for the treatment of trauma-associated coagulopathy.
abstract: BACKGROUND
  Trauma-associated coagulopathy carries an extremely high mortality. Fresh-frozen plasma (FFP) is the mainstay of treatment; however, its availability in the battlefield is limited. We have already shown that lyophilized, freeze-dried plasma (FDP) reconstituted in its original volume can reverse trauma-associated coagulopathy. To enhance the logistical advantage (lower volume and weight), we developed and tested a hyperoncotic, hyperosmotic spray-dried plasma (SDP) product in a multiple injuries/hemorrhagic shock swine model.
  
  
  METHODS
  Plasma separated from fresh porcine blood was stored as FFP or preserved as FDP and SDP. In in vitro testing, SDP was reconstituted in distilled water that was either equal (1 × SDP) or one-third (3 × SDP) the original volume of FFP. Analysis included measurements of prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen levels, and activity of selected clotting factors. In in vivo testing, swine were subjected to multiple injuries (femur fracture and grade V liver injury) and hemorrhagic shock (60% arterial hemorrhage, with the "lethal triad" of acidosis, coagulopathy, and hypothermia) and were treated with FFP, FDP, or 3 × SDP (n=4-5/group). Coagulation profiles (PT, PTT, and thromboelastography) were measured at baseline, post-shock, post-crystalloid, treatment (M0), and during 4 hours of monitoring (M1-4).
  
  
  RESULTS
  In vitro testing revealed that clotting factors were preserved after spray drying. The coagulation profiles of FFP and 1 × SDP were similar, with 3 × SDP showing a prolonged PT/PTT. Multiple injuries/hemorrhagic shock produced significant coagulopathy, and 3 × SDP infusion was as effective as FFP and FDP in reversing it.
  
  
  CONCLUSIONS
  Plasma can be spray dried and reconstituted to one-third of its original volume without compromising the coagulation properties in vivo. This shelf-stable, low-volume, hyperoncotic, hyperosmotic plasma is a logistically attractive option for the treatment of trauma-associated coagulopathy in austere environments, such as a battlefield.
authors: Department of Surgery, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts 02114, USA.
authors: Fahad
authors: F
authors: Shuja
authors: Robert A
authors: RA
authors: Finkelstein
authors: Eugene
authors: E
authors: Fukudome
authors: Michael
authors: M
authors: Duggan
authors: Tareq
authors: T
authors: Kheirbek
authors: Kristopher
authors: K
authors: Hamwi
authors: Thomas H
authors: TH
authors: Fischer
authors: Karim
authors: K
authors: Fikry
authors: Marc
authors: M
authors: deMoya
authors: George C
authors: GC
authors: Velmahos
authors: Hasan B
authors: HB
authors: Alam